Alexandra Monceau,Rasya Gokul Nath,Xavier Suárez-Calvet,Olimpia Musumeci,Antonio Toscano,Biruta Kierdaszuk,Anna Kostera-Pruszczyk,Cristina Domínguez- González,Aurelio Hernández-Lain,Carmen Paradas,Eloy Rivas,George Papadimas,Constantinos Papadopoulos,Margarita Chrysanthou-Piterou,Eduard Gallardo,Montse Olivé,James Lilleker,Mark E Roberts,Domenica Marchese,Giulia Lunazzi,Holger Heyn,Esther Fernández-Simón,Elisa Villalobos,James Clark,Panos Katsikis,Catherine Collins,Priyanka Mehra,Zoe Laidler,Amy Vincent,Giorgio Tasca,Chiara Marini-Bettolo,Michela Guglieri,Volker Straub,Nina Raben,Jordi Díaz-Manera

Abstract:Late-onset Pompe Disease (LOPD) is a rare genetic disorder caused by the deficiency of acid alpha-glucosidase leading to progressive cellular dysfunction due to the accumulation of glycogen in the lysosome. The mechanism of relentless muscle damage – a classic manifestation of the disease – has been extensively studied by analysing the whole muscle tissue; however, little, if any, is known about transcriptional heterogeneity among nuclei within the multinucleated skeletal muscle cells. This is the first report of application of single nuclei RNA sequencing to uncover changes in the gene expression profile in muscle biopsies from eight patients with LOPD and four muscle samples from age and gender matched healthy controls. We matched these changes with histology findings using GeoMx Spatial Transcriptomics to compare the transcriptome of control myofibers from healthy individuals with non-vacuolated (histologically unaffected) and vacuolated (histologically affected) myofibers of LODP patients. We observed an increase in the proportion of slow and regenerative muscle fibers and macrophages in LOPD muscles. The expression of the genes involved in glycolysis was reduced, whereas the expression of the genes involved in the metabolism of lipids and amino acids was increased in non-vacuolated fibers, indicating early metabolic abnormalities. Additionally, we detected upregulation of autophagy genes, and downregulation of the genes involved in ribosomal and mitochondrial function leading to defective oxidative phosphorylation. The upregulation of the genes associated with inflammation, apoptosis and muscle regeneration was observed only in vacuolated fibers. Notably, enzyme replacement therapy – the only available therapy for the disease – showed a tendency to restore metabolism dysregulation, particularly within slow fibers. A combination of single nuclei RNA sequencing and spatial transcriptomics revealed the landscape of normal and the diseased muscle, and highlighted the early abnormalities associated with the disease progression. Thus, the application of these two new cutting-edge technologies provided insight into the molecular pathophysiology of muscle damage in LOPD and identified potential avenues for therapeutic intervention.

Molecular diagnosis of Pompe disease using MALDI TOF/TOF and 1H NMR

Brain glycogen build-up measured by magnetic resonance spectroscopy in classic infantile Pompe disease

Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease

Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding

Molecular Approaches for the Treatment of Pompe Disease

Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease (vol 63, 1271, 2017)

A new diagnostic assay for glycogen storage disease type II in mixed leukocytes

Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases

Laboratory diagnosis of the neuromuscular glycogen storage diseases

From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges

Development of a rapid simultaneous assay of two urinary tetrasaccharide metabolites using differential ion mobility and tandem mass spectrometry and its application to patients with glycogen storage disease (type Ib and II)

Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model

PO-0384 The Practical Method To Diagnosis Of Fourteen Cases Of Glycogen Storage Diseases In Our Laboratory

Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease

Pompe Disease: New Developments in an Old Lysosomal Storage Disorder

Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders

Decoding the muscle transcriptome of patients with late onset Pompe disease reveals markers of disease progression

Two fluorimetric determinations of acid α-glucosidase activity in dried blood spot: Pompe disease in Iranian population

Muscle diffusion MRI reveals autophagic buildup in a mouse model for Pompe disease

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

Interplay between mitochondrial dysfunction and lysosomal storage: challenges in genetic metabolic muscle diseases with a focus on infantile onset Pompe disease